GRAIL公司经理在各种分析家的看法和最近的收入节减中出售了670K美元股票。 GRAIL executives sold $670K in stock amid mixed analyst views and a recent earnings beat.

2026年3月5日和9日,包括CEO Robert Ragusa、Joshua Ofman和CFO Aaron Freidin在内的数名GRAIL公司总裁分别分别出售了12 000多股股票,共计约670 000美元。 On March 5 and 9, 2026, several GRAIL executives, including CEO Robert Ragusa, President Joshua Ofman, and CFO Aaron Freidin, sold a combined total of over 12,000 shares, totaling approximately $670,000, in separate transactions. 据SEC文件披露,拉古萨在3月9日进行的最大销售将其股份减少了1.15%. The sales were disclosed in SEC filings, with Ragusa’s largest sale on March 9 reducing his stake by 1.15%. GRAIL于2月19日报告第四季度收入,每股损失2.44美元,高于预期的3.33美元损失,收入4 360万美元,略高于预测。 GRAIL reported fourth-quarter earnings on February 19, posting a loss of $2.44 per share—better than the expected $3.33 loss—with revenue of $43.6 million, slightly above forecasts. 该公司利用无细胞DNA和机器学习开发GalleriTM多癌症早期血液检测测试,市场上限为19.4亿美元。 The company, which develops the Galleri™ multi-cancer early detection blood test using cell-free DNA and machine learning, has a market cap of $1.94 billion. 分析员持有不同意见,有一致的“持股”评级,目标价格为90.17美元。 Analysts hold mixed views, with a consensus “hold” rating and a target price of $90.17. 3月10日,库存关闭49.82美元,减少了0.41美元,交易量低于平均数。 The stock closed at $49.82 on March 10, down $0.41, with trading volume below average.